Latest market price
10.63
-0.13-1.21%
OverviewShort InterestFilings
GLUEQT20Monte Rosa Therapeutics, Inc.·NASDAQ
10.63-1.21%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)-1.86Insider Own—Shs Outstand85.31MPerf Week1.43%
Market Cap906.88MForward P/E—EPS next Y-1.86Insider Trans-0.10%Shs Float60.17MPerf Month1.24%
Enterprise Value323.88MPEG—EPS next Q-0.24Short Float34.34%Perf Quarter-33.89%
Income-39.00MP/S7.31EPS this Y—Short Ratio15.17Perf Half Y-45.68%
Sales124.00MP/B1.86EPS next Y—ROA-23.15%Short Interest20.66MPerf YTD-32.21%
Book/sh5.71P/C1.46EPS next 5Y—ROE-43.31%52W High25.77 -58.75%Perf Year-18.29%
Cash/sh7.28P/FCF—EPS past 3/5Y—ROIC-28.19%52W Low9.68 9.81%Perf 3Y325.20%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin92.94%Volatility4.82% 5.48%Perf 5Y-54.42%
Dividend TTM—EV/Sales2.61EPS Y/Y TTM-826.67%Oper. Margin-633.04%ATR (14)0.61Perf 10Y—
Dividend Ex-Date—Quick Ratio9.52Sales Y/Y TTM-83.71%Profit Margin-560.85%RSI (14)43.15Recom2.20
Dividend Gr. 3/5Y—Current Ratio9.52EPS Q/Q-186.67%SMA201.14%Beta1.34Target Price24.83
Payout0.00%Debt/Eq0.08Sales Q/Q-60.87%SMA50-11.44%Rel Volume1.38Prev Close10.76
Employees173LT Debt/Eq0.07EarningsNov 05SMA200-38.60%Avg Volume1.28MPrice10.63
IPO DateJun 24, 2021Option/ShortYes / YesEPS/Sales Surpr.-13.02% -30.31%Net Debt/EBITDA—Volume1,764,047Change-1.21%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-11-26ReiteratedUBSBuy$19
Oct-05-26ReiteratedRaymond James$25
Aug-07-26ReiteratedGuggenheimBuy$35 → $28
Aug-03-26ReiteratedWedbushOutperform$37 → $27
Jul-31-26ReiteratedJefferiesBuy$40 → $25
Jul-27-26ReiteratedJefferiesBuy$31 → $40
Jun-30-26ReiteratedGuggenheimBuy$35
Jan-14-26ReiteratedPiper SandlerOverweight$37
Jan-07-26ReiteratedJefferiesBuy$22 → $31
Jan-07-26ReiteratedWedbushOutperform$26 → $37
Latest News· Times ET
Oct-29-26
Oct-29-2611:06AM
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Releasezacks.com
Oct-28-26
Oct-28-2607:00AM
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)Yahoo
Oct-23-26
Oct-23-2606:51AM
Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?Yahoo
Oct-16-26
Oct-16-2602:45AM
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Has Consensus Target Price of $26.67 According to Analystsdefenseworld.net
Oct-11-26
Oct-11-2602:44AM
ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Surveydefenseworld.net
Oct-06-26
Oct-06-2603:02AM
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Studymarketbeat.com
Oct-02-26
Oct-02-2604:01PM
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Oct-01-26
Oct-01-2604:00PM
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcriptseekingalpha.com
12:44PM
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Diseasebenzinga.com
07:00AM
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Riskglobenewswire.com
Sep-30-26
Sep-30-2605:00PM
These stocks are moving in today's after hours sessionChartMill
04:01PM
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Riskglobenewswire.com
Sep-28-26
Sep-28-2603:23AM
Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DEdefenseworld.net
Sep-21-26
Sep-21-2602:45AM
Analysts Set Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Target Price at $28.50defenseworld.net
01:59AM
Financial Contrast: Monte Rosa Therapeutics (NASDAQ:GLUE) & Cardiff Oncology (NASDAQ:CRDF)defenseworld.net
Company

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue124760————
Cost of Goods Sold Incl. D&A886————
Gross Profit11568-6————
Selling, General and Administrative Excl. Other363532————
Research and Development142122105————
Other Operating Expense-8-80————
Operating Income-54-81-143————
Interest Expense
000————
Unusual Expense
———————
Non-Operating Income (Expense)14118————
Net Income Before Taxes-40-70-135————
Income Taxes-130————
Consolidated Net Income-39-73-135————
Net Income From Continuing Operations-39-73-135————
Net Income-39-73-135————
EPS (Recurring)-0.59-0.98-2.63————
EPS (Basic, Before Extraordinaries)-0.59-0.98-2.63————
EPS (Diluted)-0.59-0.98-2.63————
EBITDA-31-62-129————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio8.356.76—————
Gross Margin92.7489.47—————
Operating Margin-43.55-106.58—————
Net Margin-31.45-96.05—————
Shares Outstanding667451————
Market Capitalization1,035514288————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$28.42$21.68$14.95$8.22$1.48● Close Price0.00M0.42M0.85M1.27M1.69MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bowen MatthewPrincipal Accounting OfficerOct 05 '26Sale10.561313725,891Oct 06
Warmuth MarkusPresident & CEOJul 16 '26Sale23.189,500220,219585,038Jul 17
Champoux JenniferChief Operating OfficerJul 15 '26Sale23.384,351101,73062,371Jul 16
Champoux JenniferChief Operating OfficerJul 15 '26Option Exercise3.984,35117,31766,722Jul 16
Townson SharonChief Scientific OfficerJul 06 '26Sale23.316,000139,84967,845Jul 07
Townson SharonChief Scientific OfficerJul 06 '26Option Exercise6.146,00036,84073,845Jul 07
Janku FilipChief Medical OfficerJun 30 '26Option Exercise13.415,40772,50866,019Jul 01
Janku FilipChief Medical OfficerJun 30 '26Sale24.505,407132,47260,612Jul 01
Manning Anthony M.DirectorJun 29 '26Option Exercise4.1610,00041,60010,000Jun 30
Janku FilipChief Medical OfficerJun 29 '26Option Exercise7.566,00045,36065,992Jun 30
Janku FilipChief Medical OfficerJun 29 '26Sale22.956,000137,70059,992Jun 30
Manning Anthony M.DirectorJun 29 '26Sale23.1110,000231,1000Jun 30
Janku FilipChief Medical OfficerJun 24 '26Option Exercise7.5630,000226,80089,992Jun 25
Janku FilipChief Medical OfficerJun 24 '26Sale21.4230,000642,68159,992Jun 25
Janku FilipChief Medical OfficerJun 23 '26Sale20.2211,845239,52259,992Jun 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.